SynthesisBMC cancer2026
Clinical significance of the pretreatment C-reactive protein-albumin-lymphocyte (CALLY) index in colorectal cancer patients: a meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CALLY Index and Inflammatory Parameters for Predicting Focal Involvement in Human Brucellosis: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- An albumin-based immune-nutritional score for predicting complete response, organ preservation, and toxicity after neoadjuvant PD-1-based therapy in low rectal cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe C-reactive protein-albumin-lymphocyte (CALLY) index, which is devised to evaluate the inflammatory, immune, and nutritional status of patients, has emerged as a potentially valuable prognostic biomarker in diverse malignancies. The aim of this study is to conduct a systematic investigation into the correlation between the pretreatment CALLY index and clinical outcomes in patients with colorectal cancer.
methodsA comprehensive systematic literature search was carried out using electronic databases, including Web of Science, PubMed, CNKI and Embase. The search spanned from inception to July 1, 2025, with an update on September 20, 2025. The primary endpoints were survival outcomes and postoperative complications, while the secondary outcomes were clinicopathological features. This meta-analysis has been registered with PROSPERO (CRD420251156757).
resultsA total of ten studies, involving 7,362 patients with colorectal cancer, were included in the meta-analysis. The pooled findings indicated that patients in the high CALLY group demonstrated significantly better overall survival (Hazard ratio [HR] = 0.62; 95% confidence interval [CI]: 0.53–0.73; I² = 69%), better disease-free survival (HR = 0.58; 95% CI: 0.41–0.81; I² = 84%), and a lower risk of postoperative complications (Odds ratio [OR] = 0.55; 95% CI: 0.38–0.81; I² = 29%) compared to those in the low CALLY group. Moreover, a high CALLY index was significantly associated with a lower percentage of T4 tumors and a lower proportion of poorly differentiated histology.
conclusionsOur evidence suggests that the pretreatment CALLY index holds potential as a valuable biomarker to predict clinical outcomes for patients with colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.